Viking Therapeutics (VKTX) Research & Development (2016 - 2025)
Historic Research & Development for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $153.5 million.
- Viking Therapeutics' Research & Development rose 39523.67% to $153.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $345.0 million, marking a year-over-year increase of 23937.66%. This contributed to the annual value of $345.0 million for FY2025, which is 23937.57% up from last year.
- Per Viking Therapeutics' latest filing, its Research & Development stood at $153.5 million for Q4 2025, which was up 39523.67% from $90.0 million recorded in Q3 2025.
- Viking Therapeutics' 5-year Research & Development high stood at $153.5 million for Q4 2025, and its period low was $9.8 million during Q4 2021.
- In the last 5 years, Viking Therapeutics' Research & Development had a median value of $17.3 million in 2022 and averaged $30.5 million.
- As far as peak fluctuations go, Viking Therapeutics' Research & Development crashed by 1232.18% in 2023, and later skyrocketed by 39523.67% in 2025.
- Over the past 5 years, Viking Therapeutics' Research & Development (Quarter) stood at $9.8 million in 2021, then surged by 64.29% to $16.2 million in 2022, then rose by 26.73% to $20.5 million in 2023, then soared by 51.14% to $31.0 million in 2024, then soared by 395.24% to $153.5 million in 2025.
- Its last three reported values are $153.5 million in Q4 2025, $90.0 million for Q3 2025, and $60.2 million during Q2 2025.